Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Adults Clear all
Completed Phase 1 Interventional

Ebola and Marburg Virus Vaccines

NCT00605514
View directory record Official record
Conditions
Ebola Vaccines, Marburg Virus Disease, Ebola Virus Disease, Marburgvirus, Ebolavirus
Interventions
VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3549492 in Healthy Weight Adult Participants

NCT07085468
View directory record Official record
Conditions
Healthy
Interventions
LY3549492, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Scottsdale, Arizona • Covina, California • Northridge, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

NCT02246465
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
RXI-109
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Beverly Hills, California • Lake Worth, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 27, 2026, 7:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05701800
View directory record Official record
Conditions
Herpes Zoster
Interventions
mRNA-1468, Placebo, Shingrix
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
19
States / cities
Los Angeles, California • Longmont, Colorado • Lakeland, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

NCT00793000
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
PF-04287881, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

NCT06611033
View directory record Official record
Conditions
Healthy
Interventions
V118C, V118, PREVNAR 20™, Saline
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Hallandale, Florida • Hollywood, Florida • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

NCT05176873
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
DZD8586, Placebo
Drug
Lead sponsor
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 27, 2026, 7:41 PM EDT
Recruiting Phase 1 Interventional

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

NCT07237659
View directory record Official record
Conditions
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Interventions
NTR1011
Drug
Lead sponsor
Neutrolis
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Apple Valley, California • Beverly Hills, California • Covina, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

NCT00712803
View directory record Official record
Conditions
Dengue
Interventions
rDEN3-3'D4delta30
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 27, 2026, 7:41 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214
View directory record Official record
Conditions
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Placebo (PB)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
6
States / cities
Glendale, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

NCT01122784
View directory record Official record
Conditions
Plague Vaccine
Interventions
rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
11
States / cities
San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

NCT04338711
View directory record Official record
Conditions
Healthy
Interventions
tofacitinib modified release (MR)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

NCT01364571
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
16
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chikungunya Virus Vaccine Trial in Healthy Adults

NCT01489358
View directory record Official record
Conditions
Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
Interventions
VRC-CHKVLP059-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants

NCT05271799
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05585632
View directory record Official record
Conditions
SARS-CoV-2, Influenza, RSV
Interventions
mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
14
States / cities
DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

NCT00617344
View directory record Official record
Conditions
Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
Interventions
Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
5
States / cities
Hoover, Alabama • San Diego, California • Vallejo, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

NCT03381664
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

NCT04173819
View directory record Official record
Conditions
HIV-1-infection
Interventions
3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 45 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

NCT00833378
View directory record Official record
Conditions
Hepatitis C
Interventions
Eltrombopag, Lopinavir/Ritonavir, Eltrombopag and Lopinavir/Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 27, 2026, 7:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
View directory record Official record
Conditions
Phenylketonuria, Healthy
Interventions
SYNB1618, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 27, 2026, 7:41 PM EDT